The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that drives the
generation of myeloid cell subsets including neutrophils, monocytes, macrophages, and …

Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

Immune checkpoint inhibitors have revolutionized medical oncology, although currently only
a subset of patients has a response to such treatment. A compelling body of evidence …

Summary RNA N 6-methyladenosine (m 6 A) modification is implicated in cancer
progression. However, the impact of m 6 A on the antitumor effects of radiotherapy and the …

The emergence of immunotherapy has been an astounding breakthrough in cancer
treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have …